KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) EPS (Basic) (2016 - 2026)

Palvella Therapeutics has reported EPS (Basic) over the past 10 years, most recently at -$0.13 for Q3 2022.

  • Quarterly EPS (Basic) rose 45.83% to -$0.13 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$0.34 through Dec 2022, up 50.72% year-over-year, with the annual reading at -$3.71 for FY2025, 52.62% up from the prior year.
  • EPS (Basic) was -$0.13 for Q3 2022 at Palvella Therapeutics, up from -$0.14 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$0.0 in Q2 2018 and troughed at -$0.26 in Q4 2020.
  • The 5-year median for EPS (Basic) is -$0.13 (2021), against an average of -$0.14.
  • Year-over-year, EPS (Basic) skyrocketed 98.37% in 2018 and then tumbled 6282.23% in 2019.
  • A 5-year view of EPS (Basic) shows it stood at -$0.21 in 2018, then soared by 71.43% to -$0.06 in 2019, then tumbled by 333.33% to -$0.26 in 2020, then surged by 50.0% to -$0.13 in 2021, then changed by 0.0% to -$0.13 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's EPS (Basic) are -$0.13 (Q3 2022), -$0.14 (Q2 2022), and -$0.07 (Q1 2022).